Hospital
Coquille Valley Hospital District
Coquille Valley Hospital District was paid $7.30M by Medicaid between Jan 2018 and Nov 2024, across 101 billing codes. Its largest line is 99283, emergency room visit (moderate) — 24% of everything it billed.
33Billing provider infoCOQUILLE VALLEY HOSPITAL DISTRICT
COQUILLE, OR 97423
COQUILLE, OR 97423
33aNPI1730223967assigned 02/19/2007
33bProvider typeCritical Access Hospital
28Total paid$7.30M
24GClaims150,164
24DCodes billed101
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Critical Access Hospital providers in Oregon
Rank by total paid#11 of 22
Median peer was paid$3.52M
This provider vs. median2.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 22,358 | $1.15M | |
| 2019 | 23,844 | $1.05M | |
| 2020 | 14,721 | $694K | |
| 2021 | 20,265 | $956K | |
| 2022 | 23,630 | $1.21M | |
| 2023 | 22,904 | $1.14M | |
| 2024incomplete | 22,442 | $1.11M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 14,266 | 9,174 | $1.74M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 8,724 | 5,627 | $1.39M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.8% | 2,585 | 1,494 | $498K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.5% | 5,967 | 3,877 | $475K |
| 80053 | Comprehensive metabolic panel | 6.4% | 14,598 | 11,959 | $468K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 5.6% | 9,828 | 5,987 | $405K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.0% | 15,610 | 12,636 | $290K |
| 36415 | Collection of venous blood by venipuncture | 2.5% | 21,223 | 16,506 | $180K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.0% | 5,811 | 3,461 | $149K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.8% | 4,308 | 3,783 | $132K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.7% | 865 | 747 | $121K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.6% | 954 | 783 | $120K |
89 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.4% | 1,179 | $105K |
| 80061 | Lipid panel | 1.4% | 3,476 | $100K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.3% | 3,813 | $93K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,072 | $66K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 217 | $65K |
| 81001 | <1% | 5,595 | $56K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 599 | $55K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 798 | $55K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,187 | $49K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 598 | $49K |
| 84484 | <1% | 1,237 | $47K | |
| 84439 | <1% | 1,922 | $46K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,704 | $42K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 294 | $41K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 818 | $31K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 391 | $27K |
| 90837 | Psychotherapy session, about an hour | <1% | 206 | $23K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 359 | $22K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,091 | $21K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 51 | $19K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 335 | $18K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 21 | $14K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 258 | $14K |
| 83690 | <1% | 308 | $13K | |
| 72100 | <1% | 131 | $12K | |
| 86769 | <1% | 268 | $11K | |
| 83735 | <1% | 567 | $11K | |
| 87088 | <1% | 483 | $11K | |
| 85610 | <1% | 1,755 | $10K | |
| 0012A | <1% | 489 | $10K | |
| 86140 | <1% | 494 | $10K | |
| 82607 | <1% | 226 | $10K | |
| 0011A | <1% | 471 | $9K | |
| A9270 | Non-covered item or service | <1% | 5,539 | $9K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 346 | $9K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 66 | $9K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 236 | $8K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 228 | $8K |
| 82728 | <1% | 164 | $7K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 59 | $7K |
| 83605 | <1% | 205 | $7K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 132 | $7K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 561 | $7K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 38 | $6K |
| 83874 | <1% | 199 | $6K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 67 | $6K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 660 | $5K |
| 85652 | <1% | 334 | $5K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 377 | $5K |
| 87186 | <1% | 149 | $4K | |
| 83880 | <1% | 91 | $4K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 25 | $4K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 52 | $4K |
| 0064A | <1% | 205 | $4K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 219 | $4K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 36 | $3K |
| 73030 | <1% | 37 | $3K | |
| 83550 | <1% | 138 | $3K | |
| 82553 | <1% | 92 | $3K | |
| 83540 | <1% | 127 | $2K | |
| 94762 | <1% | 30 | $2K | |
| 93793 | <1% | 352 | $2K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 64 | $2K |
| 82550 | <1% | 94 | $2K | |
| 73562 | <1% | 26 | $1K | |
| 90686 | <1% | 86 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 148 | $1K |
| 82150 | <1% | 56 | $998.69 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 23 | $993.57 |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 34 | $957.71 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 31 | $940.11 |
| 82570 | <1% | 57 | $914.64 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 49 | $866.70 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 72 | $773.53 |
| 96127 | <1% | 191 | $741.46 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 32 | $729.49 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 143 | $674.35 |
| 82746 | <1% | 13 | $654.78 | |
| 86038 | <1% | 12 | $640.50 | |
| 36416 | <1% | 958 | $568.55 | |
| 86703 | <1% | 15 | $524.70 | |
| 87400 | <1% | 27 | $495.00 | |
| 86803 | <1% | 15 | $472.71 | |
| 80069 | <1% | 19 | $314.82 | |
| 86780 | <1% | 13 | $294.32 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 24 | $291.02 |
| 82043 | <1% | 14 | $152.15 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 16 | $136.70 |
| 99406 | <1% | 16 | $110.30 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLANG, JEFFREY (CEO)